Tumour M2-PK as a predictor of surgical outcome in ovarian cancer, a prospective cohort study

European Journal of Gynaecological Oncology

Volumn 28, Issue 2, 2007, Pages 103-108

  Ahmed, A S ^a,c   Dew, T ^a   Lawton, F G ^a   Papadopoulos, A J ^b   Devaja, O ^b   Raju, K S ^a   Sherwood, R A ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b MAIDSTONE HOSPITAL   (United Kingdom)

^c Maidstone Hospital ^*  (United Kingdom)

Author keywords

Cytoreduction; Diagnosis; Ovarian cancer; Pyruvate kinase; Tumour marker

Indexed keywords

CA 125 ANTIGEN; PYRUVATE KINASE; PYRUVATE KINASE M2; TUMOR MARKER; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN TUMOR; BLOOD SAMPLING; CANCER CENTER; CANCER DIAGNOSIS; CANCER INVASION; CANCER STAGING; CANCER SURGERY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; ENZYME ASSAY; ENZYME BLOOD LEVEL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CANCER; PROGNOSIS; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; UNITED KINGDOM;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; LONDON; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; OVARIECTOMY; PROSPECTIVE STUDIES; PYRUVATE KINASE; REPRODUCIBILITY OF RESULTS; ROC CURVE; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34248214180     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Parkin D.M., Bray F., Ferlay J., Pisani P.: "Global cancer statistics, 2002". CA Cancer J. Clin., 2005, 55, 74.
2. Jemal A., Tiwari R.C., Murray T., Ghafoor A., Samuels A., Ward E. et al.: "American Cancer Society. Cancer Statistics, 2004" (review). CA Cancer J. Clin., 2004, 54, 8.
3. Heintz A.P., Odicino F., Maisonneuve P., Beller U., Benedet J.L., Creasman W.T. et al.: "Carcinoma of the ovary". J Epidemiol. Biostat., 2001, 6, 107.
4. International Federation of Gynecology and Obstetrics. Annual report on the results of Treatment in Gynecological Cancer, Vol. 23, 1998.
5. Hoskins W.J., Bundy B.N., Thigpen J.T., Omura G.A.: "The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume Stage III epithelial ovarian cancer: a Gynecologic Oncology Group study". Gynecol. Oncol., 1992, 47, 159.
6. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M. et al.: "The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma". Am. J. Obstet. Gynecol., 1994, 170, 974.
7. Bristow R.E., Duska L.R., Lambrou N.C., Fishman E.K., O'Neill M.J., Trimble E.L. et al.: "A model for predicting surgical outcome in patients with advanced ovarian carcinoma using computed tomography". Cancer, 2000, 89, 1532.
8. Obeidat B., Latimer J., Crawford R.: "Can optimal primary cytoreduction be predicted in advanced stage epithelial ovarian cancer? Role of preoperative serum CA125 level". Gynecol. Obstet. Invest., 2004, 57, 153.
9. Brockbank E.C., Ind T.E., Barton D.P., Shepherd J.H., Gore M.E., A'Hern R. et al.: "Preoperative predictors of suboptimal primary surgical cytoreduction in women with clinical evidence of advanced primary epithelial ovarian cancer". Int. J. Gynecol. Cancer, 2004, 14, 42.
10. Gemer O., Lurian M., Gdalevich M., Kapustian V., Piura E., Schneider D. et al.: "A multicenter study of CA 125 level as a predictor of non-optimal primary cytoreduction of advanced epithelial ovarian cancer". Eur. J. Surg. Oncol., 2005, 31, 1006.
11. Chi D.S., Venkatraman E.S., Masson V., Hoskins W.J.: "The ability of preoperative serum CA 125 to predict optimal primary tumor cytoreduction in Stage III epithelial ovarian carcinoma". Gynecol. Oncol., 2000, 77, 227.
12. Eigenbrodt E., Kallinowski F., Ott M., Mazurek S., Vaupel P.: "Pyruvate kinase and the interaction of amino acid and carbohydrate metabolism in solid tumors". Anticancer Res., 1998, 18, 3267.
13. Mazurek S., Grimm H., Boschek C.B., Vaupel P., Eigenbrodt E.: "Pyruvate kinase type M2: a crossroad in the tumor metabolome". Br. J. Nutr., 2002, 87 (suppl. 1), S23.
14. Mazurek S., Boschek C., Hugo F., Eigenbrodt E.: "Pyruvate kinase type M2 and its role in tumor growth and spreading". Semin. Cancer Biol., 2005, 15, 300.
15. Davies A.P., Jacobs I., Woolas R., Fish A., Oram D.: "The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index". Br. J. Obstet. Gynaecol., 1993, 100, 927.
16. International Federation of Gynecology and Obstetrics: "Changes in definitions of clinical staging for carcinoma of the cervix and ovary". Am. J. Obstet. Gynecol., 1987, 156.
17. Serov S.F., Scully R.E., Sobin L.H.: "Histological typing of ovarian tumours". International Histological Classification of Tumours, No. 9, World Health Organization, Geneva, 1973.
18. Benda J.A., Zaino R.: "GOG Pathology Manual". Buffalo, Gynecologic Oncology Group, 1994.
19. Simel D.L., Samsa G.P., Matchar D.B.: "Likelihood ratios with confidence: sample size estimation for diagnostic test studies". J. Clin. Epidemiol., 1991, 44, 763.
20. Schneider J., Velcovsky H.G., Morr H., Katz N., Neu K., Eigenbrodt E.: "Comparison of the tumor markers TU M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer". Anticancer Res., 2000, 20, 5053.
21. Luftner D., Mesterharm J., Akrivakis C., Geppert R., Petrides P.E., Wernecke K.D. et al.: "Tumor type M2 pyruvate kinase expression in advanced breast cancer". Anticancer Res., 2000, 5077.
22. Roigas J., Schulze G., Raytarowski S., Jung K., Schnorr D., Loening S.A.: "TU M2 pyruvate kinase in plasma of patients with urological tumors". Tumour Biol., 2001, 22, 282.
23. Schulze G.: "The tumor marker TU M2-PK: an application in the diagnosis of gastrointestinal cancer". Anticancer Res., 2000, 20, 4961.
24. Ventrucci M., Cipolla A., Racchini C., Casadei R., Simoni P., Gullo L.: "TU M2-pyruvate kinase, a new metabolic marker for pancreatic cancer". Dig. Dis. Sci., 2004, 49, 1149.
25. Bena-Boupda N.F., Rezai S.S., Klett R., Eigenbrodt E., Bauer R.: "Value of TU M2-PK in thyroid carcinoma: a pilot study". Anti-cancer Res., 2003, 23, 5237.
26. Ugurel S., Bell N., Sucker A., Zimpfer A., Rittgen W., Schadendorf D.: "Tumor type M2 pyruvate kinase (TU M2-PK) as a novel plasma tumor marker in melanoma". Int. J. Cancer, 2005, 117, 825.
27. Griffiths C.T.: "Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma". Natl. Cancer Inst. Monogr., 1975, 42, 101.
28. Redman C.W., Warwick J., Luesley D.M., Varma R., Lawton F.G., Blackledge G.R.: "Intervention debulking surgery in advanced epithelial ovarian cancer". Br. J. Obstet. Gynaecol., 1994, 101, 142.
29. Rose P.G., Nerenstone S., Brady M.F., Clarke-Pearson D., Olt G., Rubin S.C. et al.: "Gynecologic Oncology Group. Secondary surgical cytoreduction for advanced ovarian carcinoma". N. Engl. J. Med., 20049, 351, 2489.
30. Angioli R., Palaia I., Zullo M.A., Muzii L., Manci N., Calcagno M. et al.: "Diagnostic open laparoscopy in the management of advanced ovarian cancer". Gynecol. Oncol., 2006, 100, 455.
31. Vergote I., De Wever I., Tjalma W., Van Gramberen M., Decloedt J., van Dam P.: "Neoadjuvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma: a retrospective analysis of 285 patients". Gynecol. Oncol., 1998, 71, 431.
32. Morice P., Dubernard G., Rey A., Atallah D., Pautier P., Pomel C., et al.: "Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer". J. Am. Coll. Surg., 2003. 197, 955.
33. Jacob J.H., Gershenson D.M., Morris M., Copeland L.J., Burke T.W., Wharton J.T.: "Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer". Gynecol. Oncol., 1991, 42, 146.
34. Saygili U., Guclu S., Uslu T., Erten O., Demir N., Onvural A.: "Can serum CA125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma?". Gynecol. Oncol., 2002, 86, 57.
35. Gemer O., Segal S., Kopmar A.: "Preoperative CA125 level as a predictor of non optimal cytoreduction of advanced epithelial ovarian cancer". Acta Obstet. Gynecol. Scand., 2001, 80, 583.